What types of cancers are erlotinib indicated for?

Erlotinib (Erlotinib) is an oral small molecule tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It is widely used to treat EGFR gene mutation-positive non-small cell lung cancer (NSCLC), and is also suitable for patients with specific types of pancreatic cancer. Erlotinib was initially approved by the US FDA in 2004 and is one of the earliest representatives of the EGFR-TKI class of drugs. Its main indications include second-line or third-line treatment of locally advanced or metastatic NSCLC, especially in patients with EGFR-sensitive mutations, such as patients with Exon 19 deletion or Exon 21 (L858R) point mutation. It can inhibit the proliferation and angiogenesis of tumor cells by blocking the EGFR signaling pathway, thereby delaying the progression of the disease.

In addition to lung cancer, erlotinib is also approved for the treatment of locally advanced, inoperable or metastatic pancreatic cancer in combination with gemcitabine.Gemcitabine. In this combination regimen, erlotinib can slightly extend the overall survival of patients, although the clinical benefit is slightly limited compared with lung cancer. Research has also explored its potential application in other solid tumors (such as colorectal cancer, head and neck cancer, and ovarian cancer), but because the efficacy has not met expectations, it has not been widely included in standard treatment options.

It should be noted that the efficacy of erlotinib is highly dependent on whether the patient carries an EGFR sensitive mutation. Therefore, genetic testing is required before clinical use to screen the appropriate population. In patients with mutations, erlotinib can not only prolong progression-free survival but also improve quality of life, making it an important choice in first-line or later-line treatment. However, for patients without mutations or with T790M resistance mutations, the efficacy is poor, and other new-generation targeted drugs need to be considered.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib